In vivo imaging of tumors with protease-activated near-infrared fluorescent probes

We have developed a method to image tumor-associated lysosomal protease activity in a xenograft mouse model in vivo using autoquenched near-infrared fluorescence (NIRF) probes. NIRF probes were bound to a long circulating graft copolymer consisting of poly-L-lysine and methoxypolyethylene glycol succinate. Following intravenous injection, the NIRF probe carrier accumulated in solid tumors due to its long circulation time and leakage through tumor neovasculature. Intratumoral NIRF signal was generated by lysosomal proteases in tumor cells that cleave the macromolecule, thereby releasing previously quenched fluorochrome. In vivo imaging showed a 12-fold increase in NIRF signal, allowing the detection of tumors with submillimeter-sized diameters. This strategy can be used to detect such early stage tumors in vivo and to probe for specific enzyme activity.

[1]  P. Baudhuin,et al.  Endocytosis and chloroquine accumulation during the cell cycle of hepatoma cells in culture , 1979, The Journal of cell biology.

[2]  K. Tsurugi,et al.  Presence of a thiol protease in regenerating rat-liver nuclei. Partial purification and some properties. , 1980, European journal of biochemistry.

[3]  N. Katunuma,et al.  Inhibitions by E-64 derivatives of rat liver cathepsin B and cathepsin L in vitro and in vivo. , 1980, Journal of biochemistry.

[4]  A. Barrett,et al.  E-64 [L-trans-epoxysuccinyl-leucyl-amido(4-guanidino)butane] and related epoxides as inhibitors of cysteine proteinases. , 1981, Acta biologica et medica Germanica.

[5]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[6]  A R Kennedy,et al.  Bowman-Birk soybean protease inhibitor as an anticarcinogen. , 1983, Cancer research.

[7]  J. Harper,et al.  Reaction of serine proteases with substituted isocoumarins: discovery of 3,4-dichloroisocoumarin, a new general mechanism based serine protease inhibitor. , 1985, Biochemistry.

[8]  H. Shau,et al.  Regulation of human natural killing by lysosomotropic and thiol-reactive agents. , 1985, Immunology.

[9]  L. Boccon‐Gibod.  [Prostatic-specific antigen]. , 1988, Annales d'urologie.

[10]  J. Powers,et al.  Mechanism‐based isocoumarin inhibitors for serine proteases: Use of active site structure and substrate specificity in inhibitor design , 1989, Journal of cellular biochemistry.

[11]  J. Powers,et al.  Selective isocoumarin serine protease inhibitors block RNK-16 lymphocyte granule-mediated cytolysis. , 1989, Molecular immunology.

[12]  N. Gebbia,et al.  Cathepsin D in the malignant progression of neoplastic diseases (review). , 1992, Anticancer research.

[13]  C. D. Teates,et al.  New radiopharmaceuticals and new applications in medicine. , 1993, Current problems in diagnostic radiology.

[14]  A. Kennedy.  Cancer prevention by protease inhibitors. , 1993, Preventive medicine.

[15]  A. El-Shirbiny,et al.  Prostatic specific antigen. , 1994, Advances in clinical chemistry.

[16]  R. Muschel,et al.  Metalloproteinases in tumor progression: the contribution of MMP-9. , 1994, Invasion & metastasis.

[17]  H. Rochefort,et al.  Transfected cathepsin D stimulates high density cancer cell growth by inactivating secreted growth inhibitors. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[18]  R. Weissleder,et al.  Long-circulating blood pool imaging agents , 1995 .

[19]  R. Weissleder,et al.  Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain. , 1995, The American journal of pathology.

[20]  F. Guadagni,et al.  Systemic administration of recombinant interferon alfa in carcinoma patients upregulates the expression of the carcinoma-associated antigens tumor-associated glycoprotein-72 and carcinoembryonic antigen. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Marcel Garcia,et al.  Biological and Clinical Significance of Cathepsin D in Breast Cancer Metastasis , 1996, Stem cells.

[22]  Bonnie F. Sloane,et al.  Tumor progression and angiogenesis: cathepsin B & Co. , 1996, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[23]  R. Weissleder,et al.  An adduct of cis-diamminedichloroplatinum(II) and poly(ethylene glycol)poly(L-lysine)-succinate: synthesis and cytotoxic properties. , 1996, Bioconjugate chemistry.

[24]  Bonnie F. Sloane,et al.  Cathepsin B expression in human tumors. , 1996, Advances in experimental medicine and biology.

[25]  R K Jain,et al.  Delivery of Molecular Medicine to Solid Tumors , 1996, Science.

[26]  A. Goldberg,et al.  Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. , 1996, The New England journal of medicine.

[27]  C. Meares,et al.  Pretargeting: general principles; October 10-12, 1996. , 1997, Cancer.

[28]  Erkki Ruoslahti,et al.  αv Integrins as receptors for tumor targeting by circulating ligands , 1997, Nature Biotechnology.

[29]  D. Buchsbaum,et al.  Experimental tumor targeting with radiolabeled ligands , 1997, Cancer.

[30]  M. Rusckowski,et al.  Technetium-99m labeled epidermal growth factor-tumor imaging in mice. , 2009, The journal of peptide research : official journal of the American Peptide Society.

[31]  D A Benaron,et al.  Tissue Optics , 1997, Science.

[32]  D A Benaron,et al.  Imaging brain structure and function, infection and gene expression in the body using light. , 1997, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[33]  S R Arridge,et al.  Optical imaging in medicine: I. Experimental techniques , 1997, Physics in medicine and biology.

[34]  William G. Stetler-Stevenson,et al.  Matrix Metalloproteinases , 1997, Drugs & aging.

[35]  David K. Stevenson,et al.  Tissue Optics , 1997, Science.

[36]  M S Feld,et al.  Fluorescence tomographic imaging in turbid media using early-arriving photons and Laplace transforms. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Dario Neri,et al.  Targeting by affinity–matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform , 1997, Nature Biotechnology.

[38]  J. Fujimoto,et al.  In vivo endoscopic optical biopsy with optical coherence tomography. , 1997, Science.

[39]  A. Villringer.  Functional neuroimaging. Optical approaches. , 1997, Advances in experimental medicine and biology.

[40]  D B Kopans,et al.  Updated results of the trials of screening mammography. , 1997, Surgical oncology clinics of North America.

[41]  J. Hebden,et al.  Diagnostic imaging with light. , 1997, The British journal of radiology.

[42]  S G Demos,et al.  Advances in Optical Imaging of Biomedical Media a , 1997, Annals of the New York Academy of Sciences.

[43]  K Svanberg,et al.  In vivo fluorescence imaging for tissue diagnostics. , 1997, Physics in medicine and biology.

[44]  R R Alfano,et al.  Time‐Resolved and Nonlinear Optical Imaging for Medical Applications a , 1998, Annals of the New York Academy of Sciences.

[45]  L. Stocchi,et al.  Diagnostic and therapeutic applications of monoclonal antibodies in colorectal cancer , 1998, Diseases of the colon and rectum.

[46]  M. Feld,et al.  Raman Spectroscopy and Fluorescence Photon Migration for Breast Cancer Diagnosis and Imaging , 1998, Photochemistry and photobiology.

[47]  R Weissleder,et al.  Antibody-mediated versus nontargeted delivery in a human small cell lung carcinoma model. , 1998, Bioconjugate chemistry.

[48]  J. Roh,et al.  Different expression patterns of MMP-2 and MMP-9 in breast cancer. , 1998, Oncology reports.

[49]  R Weissleder,et al.  Preclinical evaluation and phase I clinical trial of a 99mTc-labeled synthetic polymer used in blood pool imaging. , 1998, AJR. American journal of roentgenology.

[50]  W. Yu,et al.  Requirement for Specific Proteases in Cancer Cell Intravasation as Revealed by a Novel Semiquantitative PCR-Based Assay , 1998, Cell.

[51]  G. Taraboletti,et al.  Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[52]  H. Tsuzuki,et al.  Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. , 1998, Journal of medicinal chemistry.

[53]  T. Brümmendorf,et al.  Radioimmunolocalization of primary and metastatic breast cancer. , 1998, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[54]  K. Kwong,et al.  Non-invasive in vivo mapping of tumour vascular and interstitial volume fractions. , 1998, European journal of cancer.

[55]  D. Delpy,et al.  Optical Imaging in Medicine , 1998, CLEO/Europe Conference on Lasers and Electro-Optics.

[56]  M Nakajima,et al.  [Matrix metalloproteinase inhibitors]. , 2000, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.